News

Buy Solara Active Pharma Sciences Ltd For Target Rs.520 - ICICI Securities Gradual recovery; valuations comfortable Solara Active Pharma’s (Solara) Q2FY23 performance was below our estimates across all parameters. Revenue declined 15.7% YoY (+2.5%QoQ) to Rs.3.4bn (ISec: Rs.3.5bn) with slow recovery in non-regulated markets. EBITDA margin was down 970bps YoY (+430bps QoQ) to 8.1% (I-Sec: 10.5%). Solara reported a loss of Rs100mn during the quarter. It remains confident of a strong recovery H2FY23 onwards. While we believe near-term performance would remain u...
Buy Solara Active Pharma Sciences Ltd For Target Rs.520 - ICICI Securities
Buy Solara Active Pharma Sciences Ltd For Target Rs.520 - ICICI Securities
Source: ICICI Securities Ltd
6/12/2022 2:06:56 PM
Buy Solara Active Pharma Ltd For Target Rs.520 - Motilal Oswal Financial Services On track for course correction Work in progress to better outlook of Vizag facility * Solara active Pharma (SOLARA) delivered better-than-expected operating margins, driven by superior product mix and cost-control measures. With better demand for its products and inventory normalization in the distribution channel, SOLARA is expected to further improve its performance going forward. * We revise our earnings estimate to a loss of INR214m from a loss of INR341m for FY23 and slightly ra...
Buy Solara Active Pharma Ltd For Target Rs.520 - Motilal Oswal Financial Services
Buy Solara Active Pharma Ltd For Target Rs.520 - Motilal Oswal Financial Services
Source: Motilal Oswal Financial Services Ltd
12/11/2022 12:38:20 PM
Solara zooms on getting CEP approval to manufacture Ibuprofen from Vishakhapatnam Facility Solara Active Pharma Sciences is currently trading at Rs. 415.00, up by 17.35 points or 4.36% from its previous closing of Rs. 397.65 on the BSE. The scrip opened at Rs. 397.40 and has touched a high and low of Rs. 419.65 and Rs. 392.45 respectively. So far 10241 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 10 has touched a 52 week high of Rs. 1385.00 on 10-Nov-2021 and a 52 week low of Rs. 323.65 on 20-Jun-2022. Last one week high and low of t...
Solara zooms on getting CEP approval to manufacture Ibuprofen from Vishakhapatnam Facility
Solara zooms on getting CEP approval to manufacture Ibuprofen from Vishakhapatnam Facility
Source: Accord Fintech
1/11/2022 3:16:42 PM
Add Solara Active Pharma Sciences Ltd For Target Rs.721 - ICICI Securities Recovering business provides respite Solara Active Pharma (Solara) has reported better-than-estimated result in Q4FY22 led by business recovery, which achieved ~90% of normalised revenue. Revenue, EBITDA and PAT declined ~19%, ~86% and ~97%, respectively, on a YoY basis. However, sequentially, revenue grew ~260% on an impacted base of Q3FY22 which was on account of inventory adjustment. Solara announced withdrawal of merger with Aurore due to subdued performance of both the entities. While...
Add Solara Active Pharma Sciences Ltd For Target Rs.721 - ICICI Securities
Add Solara Active Pharma Sciences Ltd For Target Rs.721 - ICICI Securities
Source: ICICI Securities Ltd
2/05/2022 2:34:44 PM
Reduce Solara Active Pharma Sciences Ltd For Target Rs.908 - ICICI Securities Washed-out quarter; blurred outlook Solara Active Pharma’s (Solara) Q3FY22 performance was way below our and consensus estimates, making the quarter a complete washout. Revenues, EBITDA and PAT fell 76.5%, 181.1% and 310.3% YoY, respectively, mainly due to: 1) writeback of one-time inventories in less regulated markets; 2) sharp decline in ibuprofen volumes and realisation; and 3) decline in covid product sales. Though Solara expects most of the lost sales to be recovered in Q4FY22, ...
Reduce Solara Active Pharma Sciences Ltd For Target Rs.908 - ICICI Securities
Reduce Solara Active Pharma Sciences Ltd For Target Rs.908 - ICICI Securities
Source: ICICI Securities Ltd
4/03/2022 3:13:14 PM
Buy Solara Active Pharma Sciences Ltd For Target Rs.1,595 - ICICI Securities Destocking of Ibuprofen; Auroure merger delayed. Solara Active Pharma (Solara) reported Q2FY22 performance was below estimate specially at the profitability front due to lower demand for Ibuprofen in the regulated markets and rising costs. Revenues remained flat YoY at Rs4.0bn, EBITDA margin dropped 670/460bps YoY/QoQ to 17.9% and adjusted PAT declined 47.5% to Rs298mn. We remain positive on the long term outlook considering presence only in the API and CRAMS space thereby removing any pot...
Buy Solara Active Pharma Sciences Ltd For Target Rs.1,595 - ICICI Securities
Buy Solara Active Pharma Sciences Ltd For Target Rs.1,595 - ICICI Securities
Source: ICICI Securities Ltd
21/12/2021 12:53:16 PM
Buy Solara Active Pharma Ltd For Target Rs.1,520 - Motilal Oswal Working on multiple fronts to enhance business prospects We recently met with the management of Solara Active Pharma (SOLARA) to understand the business outlook in further detail. Here are the key takeaways: * Backward integration in Ibuprofen manufacturing and the easing of supply-side pressure have come in handy for SOLARA, given the current situation of subdued demand for the product. * SOLARA is progressing well on building a niche product pipeline and broadening its presence in ...
Buy Solara Active Pharma Ltd For Target Rs.1,520 - Motilal Oswal
Buy Solara Active Pharma Ltd For Target Rs.1,520 - Motilal Oswal
Source: Motilal Oswal Financial Services Ltd
29/11/2021 11:51:50 AM
Buy Solara Active Pharma Sciences Ltd For Target Rs.2,000 - ICICI Securities Q1 miss; outlook intact Solara Active Pharma (Solara) reported Q1FY22 performance was below estimate due to demand pressure in some products including Ibuprofen in the regulated markets and temporary shutdown of plants due to COVID-19. Consolidated revenues grew 16.4% to Rs4.1bn led by strong growth in non-regulated markets, EBITDA margin was down 160bps YoY but flat QoQ to 22.5% due to lower proportion of regulated markets and adjusted PAT grew 19.9% to Rs507mn. We remain positive on t...
Buy Solara Active Pharma Sciences Ltd For Target Rs.2,000 - ICICI Securities
Buy Solara Active Pharma Sciences Ltd For Target Rs.2,000 - ICICI Securities
Source: ICICI Securities
17/09/2021 10:59:45 AM
Buy Solara Active Pharma Ltd : Solara 2.0 to target faster growth - Motilal Oswal Buy Solara Active Pharma Ltd For Target Rs.2,050 Solara 2.0 to target faster growth * Backward integration in Ibuprofen, at the Visakhapatnam facility, makes SOLARA one of the only two fully backward integrated API players in the world. * The recently acquired ALS will enhance its Generic APIs capabilities and move SOLARA ahead in the competitive landscape in CDMO. * Solara 2.0 lays down a path for accelerated growth, better profitability by FY25, and aims to grow the CDMO segment...
Buy Solara Active Pharma Ltd : Solara 2.0 to target faster growth - Motilal Oswal
Buy Solara Active Pharma Ltd : Solara 2.0 to target faster growth - Motilal Oswal
Source: Motilal Oswal Financial Services Ltd
4/09/2021 11:14:39 AM
Weekly Tech Picks - Larsen & Toubro Infotech Limited, Adani Enterprises Limited, Solara Active Pharma Sciences Limited, Piramal Enterprises Limited By Axis Securities Larsen & Toubro Infotech Limited * On the weekly chart, the stock has witnessed 6-8 months “Consolidation Range” breakout at 4500 levels. * The stock is well placed above its 20 and 50-day SMA’s which reconfirm bullish sentiments * Rising volumes at breakout zone signals increased participation on 06 August, 2021 *Holding period is 3 to 4 weeks. correction * The stock is in strong up trend across all the time frames forming a series of higher tops and bottoms...
Weekly Tech Picks - Larsen & Toubro Infotech Limited, Adani Enterprises Limited, Solara Active Pharma Sciences Limited, Piramal Enterprises Limited By Axis Securities
Weekly Tech Picks - Larsen & Toubro Infotech Limited, Adani Enterprises Limited, Solara Active Pharma Sciences Limited, Piramal Enterprises Limited By Axis Securities
Source: Axis Securities Ltd
8/08/2021 5:04:28 PM
Buy Solara Active Pharma Ltd For Target Rs.2,004 - ICICI Securities Strong growth continues Solara Active Pharma (Solara) reported strong growth in Q4FY21 led by healthy growth in the non-regulated markets. Consolidated revenues grew 49.7% to Rs4.4bn led by growth across geographies, adjusted EBITDA margin was up 540bps YoY but declined 240bps QoQ to 22.3% and adjusted PAT grew 217.7% to Rs566mn. We believe the key moats of the company: 1) presence only in the API and CRAMS space thereby removing any potential conflict with clients, 2) maintaining la...
Buy Solara Active Pharma Ltd For Target Rs.2,004 - ICICI Securities
Buy Solara Active Pharma Ltd For Target Rs.2,004 - ICICI Securities
Source: ICICI Securities Ltd
3/06/2021 10:19:42 AM
Buy Solara Active Pharma Ltd For Target Rs.2,000 - Motilal Oswal ‘Partner of Choice’ in API/CRAMS space * Solara Active Pharma Sciences (SOLARA) has a differentiated business model, formed by demerging the API business of Strides Pharma and integrating it with the Human API business of Sequent Scientific. While young in terms of listing, it has almost three decades of experience, with sales of INR16.2b / an EBITDA margin of 23.9% over the past 12M. * SOLARA has built a multi-pronged strategy through a) capacity expansion in core products,...
Buy Solara Active Pharma Ltd For Target Rs.2,000 - Motilal Oswal
Buy Solara Active Pharma Ltd For Target Rs.2,000 - Motilal Oswal
Source: Motilal Oswal Financial Services Ltd
19/05/2021 12:22:36 PM
Solara Active Pharma Q4 net profit zooms 214.36% at Rs 57.15 cr The company reported standalone net profit of Rs 57.15 crore for the quarter ended March 31, 2021 as compared to Rs 18.18 crore in the same period last year, registering a year-on-year growth of 214.36 per cent. Net revenue of the company rose substantially by 49.68 per cent at Rs 444.21 crore in January-March quarter of this fiscal as against Rs 296.77 crore in the corresponding period last year. During January-March quarter, operating expenses increased by 39.84 per cent to Rs 344.70 cro...
Solara Active Pharma Q4 net profit zooms 214.36% at Rs 57.15 cr
Solara Active Pharma Q4 net profit zooms 214.36% at Rs 57.15 cr
Source: Dion Global Solutions Ltd
7/05/2021 2:12:34 PM